Clinical Trials Browser

Phase 1/2 × Recurrence × Melphalan × Clear all

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence